KR20230040957A - 치료제를 국소 전달하기 위한 약물 전달 시스템 및 이의 용도 - Google Patents

치료제를 국소 전달하기 위한 약물 전달 시스템 및 이의 용도 Download PDF

Info

Publication number
KR20230040957A
KR20230040957A KR1020227045471A KR20227045471A KR20230040957A KR 20230040957 A KR20230040957 A KR 20230040957A KR 1020227045471 A KR1020227045471 A KR 1020227045471A KR 20227045471 A KR20227045471 A KR 20227045471A KR 20230040957 A KR20230040957 A KR 20230040957A
Authority
KR
South Korea
Prior art keywords
methyl
drug delivery
amino
delivery system
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227045471A
Other languages
English (en)
Korean (ko)
Inventor
하오 쟝
웨이지앙 쟝
리츈 펭
구올롱 우
다펭 리
Original Assignee
코발 바이오파마 (상하이) 컴퍼니 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 코발 바이오파마 (상하이) 컴퍼니 리미티드 filed Critical 코발 바이오파마 (상하이) 컴퍼니 리미티드
Publication of KR20230040957A publication Critical patent/KR20230040957A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020227045471A 2020-07-15 2021-07-13 치료제를 국소 전달하기 위한 약물 전달 시스템 및 이의 용도 Pending KR20230040957A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2020/102115 2020-07-15
CN2020102115 2020-07-15
PCT/CN2021/105899 WO2022012492A1 (en) 2020-07-15 2021-07-13 Drug delivery system for locally delivering therapeutic agents and uses thereof

Publications (1)

Publication Number Publication Date
KR20230040957A true KR20230040957A (ko) 2023-03-23

Family

ID=79555042

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227045471A Pending KR20230040957A (ko) 2020-07-15 2021-07-13 치료제를 국소 전달하기 위한 약물 전달 시스템 및 이의 용도

Country Status (10)

Country Link
US (1) US20230256106A1 (cg-RX-API-DMAC7.html)
EP (1) EP4181963A4 (cg-RX-API-DMAC7.html)
JP (1) JP7870259B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230040957A (cg-RX-API-DMAC7.html)
CN (2) CN117838875B (cg-RX-API-DMAC7.html)
AU (1) AU2021310171A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022021179A2 (cg-RX-API-DMAC7.html)
CA (1) CA3179897A1 (cg-RX-API-DMAC7.html)
IL (1) IL297377A (cg-RX-API-DMAC7.html)
WO (1) WO2022012492A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025018772A1 (ko) * 2023-07-17 2025-01-23 차의과학대학교 산학협력단 금 나노입자 및 상환변환 나노입자로부터 형성된 일시적 광천공을 위한 나노복합체

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114907353A (zh) * 2021-02-09 2022-08-16 明慧医药(杭州)有限公司 一种前药化合物及其制备方法和用途
KR20240027732A (ko) * 2021-07-20 2024-03-04 코발 바이오파마 (상하이) 컴퍼니 리미티드 외용 항염증 결합 화합물 약물 및 그 제조 방법과 응용
AU2022348759A1 (en) * 2021-09-16 2024-01-25 Coval Biopharma (Shanghai) Co., Ltd. Drug delivery system for locally delivering therapeutic agents and uses thereof
WO2023155905A1 (zh) * 2022-02-21 2023-08-24 上海岸阔医药科技有限公司 化合物及其用途
WO2026002095A1 (en) * 2024-06-26 2026-01-02 Coval Biopharma (Shanghai) Co., Ltd. Drug delivery system for locally controlled release of therapeutic agents and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITPD20020271A1 (it) * 2002-10-18 2004-04-19 Fidia Farmaceutici Composti chimico-farmaceutici costituiti da derivati dei taxani legati covalentemente all'acido ialuronico o ai suoi derivati.
CN101921347B (zh) 2004-01-07 2014-07-30 生化学工业株式会社 透明质酸衍生物及含有其的药剂
WO2006122954A2 (en) * 2005-05-18 2006-11-23 Eurand Pharmaceuticals Limited Antiproliferative conjugates comprising hyaluronic acid and n-derivatives of glutamic acid
IE20060049A1 (en) * 2006-01-25 2007-08-08 Eurand Pharmaceuticals Ltd A novel drug delivery system: use of hyaluronic acid as a carrier moleclue for different classes of therapeutic active agents
IE20060565A1 (en) * 2006-07-28 2008-02-06 Eurand Pharmaceuticals Ltd Drug delivery system based on regioselectively amidated hyaluronic acid
IE20070900A1 (en) * 2007-12-12 2009-06-24 Eurand Pharmaceuticals Ltd New anticancer conjugates
US9789200B2 (en) * 2008-04-22 2017-10-17 Fidia Farmaceutici S.P.A. Therapeutic use of new pharmaceutical preparations containing antitumoral drugs bound to hyaluronic acid in the treatment of neoplasias
CN101745119B (zh) * 2010-01-25 2012-07-25 中国药科大学 羧酸类药物-多糖偶联物及其制备方法与应用
BR112014032916A2 (pt) * 2012-06-28 2017-08-01 Pfizer anticorpos anti-fármacos e usos destes para o monitoramento de fármaco
CN104603156B (zh) * 2012-09-05 2016-10-26 中外制药株式会社 引入有氨基酸和甾基的透明质酸衍生物
KR101467076B1 (ko) * 2013-02-20 2014-12-02 성균관대학교산학협력단 히알루론산-메토트렉세이트 접합체를 포함하는 관절염 예방 또는 치료용 약학적 조성물 및 이의 제조방법
CN103751795B (zh) * 2013-05-20 2017-02-08 中国药科大学 透明质酸‑抗肿瘤药偶联物及复合纳米粒组合物的制备和应用
US10098962B2 (en) * 2013-07-10 2018-10-16 Seikagaku Corporation Glycosaminoglycan derivative and method for producing same
US9572832B2 (en) * 2013-08-29 2017-02-21 Holy Stone Healthcare Co., Ltd. Compound of glycosaminoglycan and its fabrication method as well as application
CN104491875A (zh) * 2014-12-22 2015-04-08 中国药科大学 一种基于透明质酸-难溶性药物前药的自聚纳米系统的制备方法
CN107096036B (zh) * 2017-04-12 2020-01-14 武汉理工大学 一种pH敏感型透明质酸-多柔比星纳米前药的制备方法及其应用
JOP20190245A1 (ar) * 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
CN108467439A (zh) * 2018-03-22 2018-08-31 盐城师范学院 一种水溶性紫杉醇抗癌药物的制备方法
JP2022510986A (ja) * 2018-12-12 2022-01-28 エージェンシー フォー サイエンス,テクノロジー アンド リサーチ ヒアルロン酸およびエピガロカテキン-3-o-没食子酸のコンジュゲートおよびナノ粒子ならびにその使用
WO2021243467A1 (en) * 2020-06-05 2021-12-09 London Pharmaceuticals And Research Corporation Cannabinoid-hyaluronic acid bioconjugates

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025018772A1 (ko) * 2023-07-17 2025-01-23 차의과학대학교 산학협력단 금 나노입자 및 상환변환 나노입자로부터 형성된 일시적 광천공을 위한 나노복합체

Also Published As

Publication number Publication date
CN117838875A (zh) 2024-04-09
CN115867319B (zh) 2024-01-02
CN117838875B (zh) 2025-01-24
CN115867319A (zh) 2023-03-28
JP2023533679A (ja) 2023-08-04
US20230256106A1 (en) 2023-08-17
CA3179897A1 (en) 2022-01-20
WO2022012492A1 (en) 2022-01-20
IL297377A (en) 2022-12-01
JP7870259B2 (ja) 2026-06-04
EP4181963A1 (en) 2023-05-24
BR112022021179A2 (pt) 2023-02-23
AU2021310171A1 (en) 2022-11-10
EP4181963A4 (en) 2025-06-25

Similar Documents

Publication Publication Date Title
CN117838875B (zh) 用于局部递送治疗剂的药物递送系统以及其用途
ES2944573T3 (es) Antagonistas de TLR7/8 y usos de los mismos
US11414394B2 (en) Process for producing a hydrate of a hydrochloride salt of 2,2′-((((((2-acetylnaphtho[2,3-b]furan-4,9-diyl)bis(oxy))bis(carbonyl))bis(azanediyl))bis(ethane-2,1-diyl))bis(azanediyl))diacetic acid
AU2018288029B2 (en) Antibody-drug conjugate having acidic self-stabilization junction
US8586705B2 (en) Macromolecular compounds having controlled stoichiometry
CN110090308B (zh) 制备偶联物的方法
JP7337898B2 (ja) 生物活性剤を含むポリマーコンジュゲート
JP2018012729A (ja) 治療剤送達のためのシクロデキストリン系ポリマー
TW202128695A (zh) 用於治療pd-l1疾病之雜芳基-聯苯基胺
TWI716342B (zh) Sn-38之緩釋結合物
TW202128651A (zh) 用於治療pd-l1疾病之雜芳基-聯苯基醯胺
KR20260047300A (ko) Tlr7/8 안타고니스트 및 이의 용도
WO2019103050A1 (ja) タンパク質結合性薬物
US20240398963A1 (en) Drug delivery system for locally delivering therapeutic agents and uses thereof
JP2026065050A (ja) Cugリピート配列の結合剤
WO2021072330A1 (en) Galnac-tgfbr1 inhibitor conjugates for the treatment of liver diseases
RU2847196C9 (ru) Система доставки лекарственных средств для локальной доставки терапевтических агентов и ее применения
RU2847196C1 (ru) Система доставки лекарственных средств для локальной доставки терапевтических агентов и ее применения
HK40107352A (en) Drug delivery system for locally delivering therapeutic agents and uses thereof
WO2026002095A1 (en) Drug delivery system for locally controlled release of therapeutic agents and uses thereof
HK40110475A (en) Drug delivery system for locally delivering therapeutic agents and uses thereof
EP2313390B1 (en) Process for the preparation of nicotine-based haptens
KR20260028651A (ko) 엽산-약물 접합체, 이의 제조 방법 및 이를 포함하는 약학적 조성물

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902